Discover relugolix (Orgovyx) - the groundbreaking oral GnRH receptor antagonist that delivers swift testosterone suppression for advanced prostate cancer, eliminating the initial surge linked to injectables.
Mechanism
Relugolix effectively blocks GnRH receptors in the anterior pituitary, halting the release of LH and FSH essential for testosterone production. This strategic disruption triggers rapid declines in testosterone, often reaching castrate levels (<50 ng/dL) within days, stifling prostate cancer growth fueled by androgens.
Research
The Phase 3 HERO trial showcased relugolix's superiority, with 56% of patients attaining castrate testosterone levels by day 4 and a remarkable 54% reduction in major adverse cardiovascular events (MACE) compared to leuprolide. This compelling data affirms relugolix's potency and safety for advanced prostate cancer management.
Synergies
Relugolix pairs seamlessly with other advanced prostate cancer treatments, such as AR pathway inhibitors and chemotherapy. Ben IQ will analyze YOUR lab results and goals to optimize your therapeutic stack.
Trade-Offs
While relugolix offers significant benefits, its higher cost relative to injectable alternatives and potential side effects like metabolic changes and cardiovascular concerns warrant individual evaluation. YOUR unique situation demands YOUR specific data.